Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors
about
New Insights into the Function of the Immunoproteasome in Immune and Nonimmune CellsImmunoproteasomes: structure, function, and antigen presentationTargeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategiesThe immunoproteasome and viral infection: a complex regulator of inflammationClinical use of proteasome inhibitors in the treatment of multiple myelomaImmunoproteasome overexpression underlies the pathogenesis of thyroid oncocytes and primary hypothyroidism: studies in humans and mice.Carfilzomib: a novel second-generation proteasome inhibitorImmunoproteasome LMP2 60HH variant alters MBP epitope generation and reduces the risk to develop multiple sclerosis in Italian female population.On to the road to degradation: atherosclerosis and the proteasomeTargeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death.Proteasome inhibitors in glioblastomaThe pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivoMolecular characterization and expressional affirmation of the beta proteasome subunit cluster in rock bream immune defense.Proteasome inhibitors in the treatment of multiple myelomaOverview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Proteasome inhibitors in cancer therapyCarfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma.Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma.Progression of cancer from indolent to aggressive despite antigen retention and increased expression of interferon-gamma inducible genesTargeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.The 26S proteasome complex: an attractive target for cancer therapyProteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedsideDifferential regulation of proteasome function in isoproterenol-induced cardiac hypertrophyProteasome inhibitors in mantle cell lymphomaSubunit specific inhibitors of proteasomes and their potential for immunomodulationA selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice.Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myelomaTargeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.MicroRNA-feedback loop as a key modulator of liver tumorigenesis and inflammation.Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome.Immunoproteasomes and immunotherapy-a smoking gun for lung cancer?Activity-based imaging probes of the proteasome.Inhibitors of the immunoproteasome: current status and future directionsThe immunoproteasome as a target in hematologic malignancies.Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses.Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis.Blockade of the malignant phenotype by β-subunit selective noncovalent inhibition of immuno- and constitutive proteasomes.IFN-γ directly controls IL-33 protein level through a STAT1- and LMP2-dependent mechanism.MUC1 immunotherapy.
P2860
Q26774372-4F05A36E-750D-4B95-838D-CF21C40BD34EQ27024527-F0A02655-2858-4E16-8848-49A1F7E8D909Q27026951-F16D0C34-8810-4D64-A563-AEA447E59A5AQ27694656-DD1D68B4-6639-4D94-9B9D-CAE17807C282Q28080999-7B29A34C-3A05-4C41-8F13-029F1B671D18Q30894991-45750F98-E235-4C2D-8662-75831067347AQ33395298-DBC0E684-BDA0-4D49-A16D-B4CA7DCF4BD2Q33533349-2FDBA9A8-6CAE-4930-B54F-4C1067699D8FQ33554513-7AF9DB98-163D-4E7E-AD5D-275266A67DF7Q33585280-92E98E26-68D7-4FD8-8CD0-980356E4E03BQ33598931-F887868B-13A3-4E75-994C-12465698E801Q33896749-A37B4B8D-649F-4751-92D8-D25F5A8CAD40Q34421574-869A8600-8553-4C32-BD18-A332608D4381Q34611676-D068F121-56F3-411B-BC77-21BDBD255ACBQ34788381-42202825-42F5-4415-A22B-83D2D9B64E82Q34939959-93F19EC7-9534-41CC-B4F7-201DFC815559Q35005087-CD9F1DFB-6892-41BF-AA45-8EEAA23A07FBQ35009005-5CF91D3F-C0A0-43B8-9823-D408F44C9646Q35024457-5B48349A-C762-46B5-B2B2-1199FF065A2AQ35079913-F2A60845-6A82-44F2-BE03-4332BC465D3AQ35214544-13AE1353-6F91-4C69-9984-E5643B93F14CQ35624079-8DE4AE79-2482-4261-9113-DFFF7C999D0DQ35989980-71DC4D3D-CADF-461F-B4BB-FE54F46D688EQ35990041-4648FAA9-CFDE-4C5D-8132-4977BF35E52CQ36028745-C9EE072E-C29F-4074-A94C-29FAE174A8D6Q36042649-2509C9E4-093A-4D9E-9F74-BF96A382F256Q36075303-D73B41B4-39CE-43B2-B590-2022278857A2Q36110746-63C2A3E8-0B16-47AA-B16D-4D1CC3E4CC8EQ36333522-B807BD4D-DBCE-4719-98DF-FB1605BF38A2Q36572465-04CD1DF3-20A5-4E7F-817B-AA43386031F4Q36710603-3582B720-1FDC-471A-80E4-A4DE9F2E6BB6Q37121401-B5594B75-20DA-4505-9F39-ABFD24B9F575Q37136304-F3FBF3A2-362C-4684-885D-384C882DCA6AQ37292307-3B6B64A2-F403-4966-A10B-AC010F36997BQ37393379-25753295-EF66-4565-99AE-2C30674FC864Q37427124-ADC716A9-5491-46DC-AE3F-1840AC8E9276Q37591113-D141270A-DF16-4184-9BF8-DB6B410F54E1Q37705854-73B4D807-2F50-4872-91BB-97B47C49E0A4Q37727601-3A73949B-5BC8-40BC-B7F6-205C18721853Q37773241-A11CA050-98D6-45EF-BC11-31FD254DD0F1
P2860
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeted inhibition of the imm ...... specific proteasome inhibitors
@en
Targeted inhibition of the imm ...... pecific proteasome inhibitors.
@nl
type
label
Targeted inhibition of the imm ...... specific proteasome inhibitors
@en
Targeted inhibition of the imm ...... pecific proteasome inhibitors.
@nl
prefLabel
Targeted inhibition of the imm ...... specific proteasome inhibitors
@en
Targeted inhibition of the imm ...... pecific proteasome inhibitors.
@nl
P2093
P2860
P1433
P1476
Targeted inhibition of the imm ...... specific proteasome inhibitors
@en
P2093
Deborah J Kuhn
Marian Orlowski
Peter M Voorhees
Sally A Hunsucker
P2860
P304
P356
10.1182/BLOOD-2008-07-171637
P407
P577
2008-12-02T00:00:00Z